Haleon plc (NYSE:HLN) Shares Purchased by Baker Tilly Wealth Management LLC

Baker Tilly Wealth Management LLC boosted its holdings in shares of Haleon plc (NYSE:HLN) by 13.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 67,384 shares of the company’s stock after acquiring an additional 8,079 shares during the period. Baker Tilly Wealth Management LLC’s holdings in Haleon were worth $643,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Rhumbline Advisers raised its position in shares of Haleon by 20.0% during the 2nd quarter. Rhumbline Advisers now owns 48,966 shares of the company’s stock worth $404,000 after purchasing an additional 8,160 shares during the last quarter. Caprock Group LLC raised its holdings in shares of Haleon by 21.9% in the second quarter. Caprock Group LLC now owns 53,410 shares of the company’s stock worth $441,000 after acquiring an additional 9,582 shares during the last quarter. PFG Investments LLC lifted its position in shares of Haleon by 24.2% in the second quarter. PFG Investments LLC now owns 24,652 shares of the company’s stock valued at $204,000 after acquiring an additional 4,811 shares in the last quarter. Wedbush Securities Inc. boosted its stake in shares of Haleon by 34.9% during the second quarter. Wedbush Securities Inc. now owns 92,366 shares of the company’s stock valued at $763,000 after acquiring an additional 23,886 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC increased its position in Haleon by 18.4% during the 2nd quarter. Dorsey & Whitney Trust CO LLC now owns 25,595 shares of the company’s stock worth $211,000 after purchasing an additional 3,985 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Trading Down 3.2 %

Shares of NYSE HLN traded down $0.30 on Friday, reaching $9.19. 4,134,510 shares of the company traded hands, compared to its average volume of 6,814,480. The company has a 50 day moving average of $9.61 and a 200 day moving average of $9.67. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a fifty-two week low of $7.89 and a fifty-two week high of $10.80. The stock has a market capitalization of $41.60 billion, a PE ratio of 27.03, a P/E/G ratio of 2.95 and a beta of 0.29.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on HLN. Morgan Stanley lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday. UBS Group upgraded shares of Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Finally, Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.